Circulating hs-CRP as Disease-Modifying Target via Astrocytic NLRP3 Inflammasom…

Elevated circulating high-sensitivity C-reactive protein (hs-CRP) serves as a disease-modifying target through direct activation of the NLRP3 inflammasome complex in astrocytes rather than microglial IL-1β amplification. Upon crossing the compromised blood-brain barrier during neuroinflammatory states, hs-CRP binds to complement receptor C1q on astrocytic membranes, triggering conformational changes that activate intracellular danger-associated molecular pattern (DAMP) recognition. This binding event initiates a calcium influx through P2X7 purinergic receptors, leading to mitochondrial dysfunction and reactive oxygen species generation. The resulting oxidative stress serves as a priming signal for NLRP3 inflammasome assembly, recruiting ASC (apoptosis-associated speck-like protein containing CARD) and pro-caspase-1 into a supramolecular complex. Activated caspase-1 cleaves pro-IL-1β and pro-IL-18 into their mature, secreted forms, while simultaneously triggering gasdermin D-mediated pyroptotic cell death in a subset of astrocytes. The released IL-1β and IL-18, along with damage-associated molecular patterns from pyroptotic astrocytes, create a self-perpetuating inflammatory cascade that recruits peripheral immune cells and activates neighboring glial populations. This astrocyte-centered mechanism differs fundamentally from microglial IL-1β amplification by emphasizing inflammasome-mediated pyroptosis as the primary driver of sustained neuroinflammation. Therapeutic targeting of hs-CRP through specific monoclonal antibodies or complement receptor antagonists could interrupt this astrocytic inflammasome activation, preventing the transition from acute to chronic neuroinflammatory states across various immunomic disorders including multiple sclerosis, Alzheimer’s disease, and autoimmune encephalitis.